News & Events
Explore the latest company news, research updates, partnerships, and development milestones from TSRLabs.
TSRL CEO Dr. Elke Lipka Selected to Present Microneedle Drug Delivery Research at PharmaEd Forum 2026
TSRL, Inc. today announced that President and CEO Dr. Elke Lipka will be presenting at the PharmaEd Microneedle & Transdermal Delivery Forum 2026, one of the leading conferences dedicated to skin-mediated therapies and advanced drug delivery technologies. The conference will be held August 27 and 28 in Providence, Rhode Island, bringing together researchers from industry, academia, and regulatory organizations to discuss the latest advances in microneedle and transdermal drug delivery.
TSRL Receives Second-Year NIH Notice of Award to Advance Microneedle Patch for Overactive Bladder Therapy
TSRL, Inc. today announced that it has received its second-year Notice of Award from the National Institutes of Health (NIH) to continue advancing its microneedle patch for the treatment of overactive bladder. The award, issued last month, provides nearly $1.1 million in continued support under Grant Number 5R44DK143799-03.
PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals
PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company and TSRL, Inc. (“TSRL”), a company focused on developing microneedle patches for the delivery of antivirals for the treatment of influenza, are pleased to announce that PharmaTher and TSRL (collectively the “Companies”) entered into a Co-Development Agreement to jointly develop a microneedle array patch with the aim to control the manufacturing and supply of microneedle patches for the Companies respective clinical and commercial drug programs.
TSRL, Inc. enters into an exclusive licensing agreement with The Queen's University of Belfast, Northern Ireland, for the use of their patented hydrogel microneedle for a flu treatment patch
TSRL, Inc., announces the continued preclinical development of a transdermal delivery system of zanamivir (Relenza®), a product licensed for the treatment and prevention of the flu.
TSRL, Inc. awarded $3M NIH grant to continue development of microneedle patch for treatment of influenza
TSRL, Inc., announces the continued development of a transdermal delivery system of zanamivir (Relenza®), an inhalation drug product licensed for the treatment and prevention of influenza A & B.
TSRL, Inc. Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza
ANN ARBOR, MICHIGAN, February 17, 2017—TSRL, Inc., announced today that the company was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). TSRL will receive approximately $600,000 over the next two years for the development of a transdermal delivery system of zanamivir (GSK, Relenza®), an inhalation drug product used in the treatment of influenza A & B.